Cutler Group LP Novo Cure LTD Transaction History

Cutler Group LP

$307 Million
Q1 2024

A detailed history of Cutler Group LP transactions in Novo Cure LTD stock. As of the latest transaction made, Cutler Group LP holds 869 shares of NVCR stock, worth $21,307. This represents 0.0% of its overall portfolio holdings.

Number of Shares

869

Previous 2,400 63.79%

Holding current value

$21,307

Previous $0 Infinity%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 19, 2024	BUY	$12.42 - $17.29 $10,792 - $15,025	869 New	869 $13,000
Q3 2023 Nov 07, 2023	SELL	$16.15 - $42.35 $26,405 - $69,242	-1,635 Reduced 94.24%	100 $1,000
Q2 2023 Jul 18, 2023	SELL	$40.29 - $82.51 $66,478 - $136,141	-1,650 Reduced 48.74%	1,735 $72,000
Q1 2023 May 01, 2023	BUY	$56.44 - $118.81 $191,049 - $402,171	3,385 New	3,385 $203,000
Q4 2021 Jan 18, 2022	BUY	$75.08 - $121.99 $485,016 - $788,055	6,460 Added 195.76%	9,760 $732,000
Q3 2021 Oct 26, 2021	BUY	$116.17 - $194.55 $185,872 - $311,280	1,600 Added 94.12%	3,300 $383,000
Q2 2021 Jul 19, 2021	BUY	$130.4 - $225.58 $156,480 - $270,696	1,200 Added 240.0%	1,700 $377,000
Q2 2020 Jul 22, 2020	SELL	$57.2 - $74.41 $48,620 - $63,248	-850 Reduced 62.96%	500 $29,000
Q1 2020 May 07, 2020	BUY	$57.05 - $95.75 $77,017 - $129,262	1,350 New	1,350 $90,000
Q4 2019 Feb 06, 2020	SELL	$68.3 - $93.8 $27,320 - $37,520	-400 Closed	0 $0
Q3 2019 Oct 28, 2019	BUY	$61.86 - $97.8 $24,744 - $39,120	400 New	400 $29,000
Q1 2018 May 11, 2018	SELL	$19.3 - $23.65 $25,205 - $30,886	-1,306 Closed	0 $0
Q4 2017 Jan 17, 2018	SELL	$16.3 - $21.9 $51,687 - $69,444	-3,171 Reduced 70.83%	1,306 $26,000
Q3 2017 Oct 17, 2017	BUY	$18.05 - $21.75 $80,809 - $97,374	4,477	4,477 $88,000

Others Institutions Holding NVCR

# of Institutions

265

Shares Held

76.5M

Call Options Held

1.17M

Put Options Held

318K

View Full List

About NovoCure Ltd

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $2.57B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

More about NVCR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.

Account